These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 25359227

  • 1. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
    Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J.
    Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
    [Abstract] [Full Text] [Related]

  • 2. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J.
    Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L.
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [Abstract] [Full Text] [Related]

  • 4. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.
    Xie L, Wei W, Pan C, Du J, Baser O.
    Adv Ther; 2011 Nov; 28(11):1000-11. PubMed ID: 22038703
    [Abstract] [Full Text] [Related]

  • 5. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [Abstract] [Full Text] [Related]

  • 6. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE, Malone DC, Trujillo JM, Gill J, Huse S, Li X, Zhou FL, Preblick R, Reid T.
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [Abstract] [Full Text] [Related]

  • 7. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
    Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta RA, Sung J, Westerbacka J, Bailey TS, Blonde L.
    Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD, Freemantle N, Gupta RA, Wu J, Nicholls CJ, Westerbacka J, Bailey TS.
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [Abstract] [Full Text] [Related]

  • 9. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B, Wiza D, Szczepanik T, Syta A, Klupa T.
    J Diabetes Res; 2020 Jan; 2020():8751348. PubMed ID: 32337298
    [Abstract] [Full Text] [Related]

  • 10. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.
    Mathieu C, Storms F, Tits J, Veneman TF, Colin IM.
    Acta Clin Belg; 2013 Jan; 68(1):28-33. PubMed ID: 23627191
    [Abstract] [Full Text] [Related]

  • 11. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
    Bailey TS, Zhou FL, Gupta RA, Preblick R, Gupta VE, Berhanu P, Blonde L.
    Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
    [Abstract] [Full Text] [Related]

  • 12. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
    Bailey TS, Wu J, Zhou FL, Gupta RA, Menon AA, Berhanu P, Westerbacka J, Van Vleet J, Blonde L.
    Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
    [Abstract] [Full Text] [Related]

  • 13. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O.
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [Abstract] [Full Text] [Related]

  • 14. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S, Wang H, Skolnik N, Tong L, Liebert RM, Lee LK, Stella P, Cali A, Preblick R.
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [Abstract] [Full Text] [Related]

  • 15. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A, Brown RE, Jiandani D, Sauriol L, Aronson R.
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [Abstract] [Full Text] [Related]

  • 16. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 17. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
    Davis KL, Tangirala M, Meyers JL, Wei W.
    Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
    [Abstract] [Full Text] [Related]

  • 18. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L, Wei W, Pan C, Baser O.
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [Abstract] [Full Text] [Related]

  • 19. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC, EDITION 2 Study Investigators.
    Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
    [Abstract] [Full Text] [Related]

  • 20. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
    Riddle MC, Yki-Järvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S, Home PD.
    Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.